Johnson & Johnson has just released their 2024 Annual Report, showcasing remarkable progress for Carvykti (cilta-cel), the revolutionary CAR T-cell therapy for relapsed or refractory multiple myeloma.
FDA Milestone:
On April 15, 2024, the U.S. FDA approved Carvykti as the first and only BCMA-targeted therapy for second-line treatment in relapsed or refractory multiple myeloma patients. This represents a groundbreaking advancement in treatment options for these patients.
Revenue Highlights:
- 2024 Total Sales: $963 million (approximately 7 billion RMB), a stunning 92.7% year-over-year growth.
- Q4 2024 Sales: $334 million, with $304 million in the U.S. and $31 million internationally, highlighting its expanding global adoption.
Why It Matters:
Carvykti’s success underscores the growing demand for innovative, cell-based therapies in oncology. With exceptional clinical outcomes, regulatory breakthroughs, and increasing global adoption, Carvykti is transforming the treatment landscape for multiple myeloma patients.
CytoArt’s Role in CAR Therapies:
Since 2018, CytoArt has been at the forefront of developing anti-idiotype antibodies (anti-ID Abs) for all FDA-approved CAR therapies, including:
Carvykti
Kymriah
Yescarta
Tecartus
Breyanzi
Abecma
As the only provider worldwide for Carvykti detection anti-ID antibodies, we are proud to support leading global pharmaceutical companies and research institutes in advancing CAR-related research and clinical innovations.
Need to Evaluate?
We offer preliminary samples to help you get started with your CAR T-cell therapy detection and research.
Let’s shape the future of oncology—together!